A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and HZ/su vaccine in Respiratory Syncytial Viruses and Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 27 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 14th largest by enrollment, is one of 2 that started in 2023, is one of 15 in phase 3, and was the 9th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 530 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 22nd largest by enrollment, is one of 4 that started in 2023, is one of 21 in phase 3, and was the 31st registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged >=50 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants of childbearing potential may be enrolled in the study, if the participant:
Exclusion Criteria:
Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration.
o In the case of COVID-19 and inactivated/subunit/split influenza vaccines, this time window can be decreased to 14 days before and after each study intervention administration provided COVID-19 vaccine use is in line with local governmental recommendations.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received both herpes zoster recombinant subunit (HZ/su) vaccine and respiratory syncytial virus prefusion protein 3 older adult (RSVPreF3 OA) vaccine on Day 1 followed by second dose of HZ/su vaccine on Day 61.
Biological: RSVPreF3 OA investigational vaccine · Biological: HZ/su vaccine
Participants received HZ/su vaccine on Day 1 and RSVPreF3 OA vaccine on Day 31 followed by second dose of HZ/su vaccine on Day 61.
Biological: RSVPreF3 OA investigational vaccine · Biological: HZ/su vaccine
One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
Also known as: Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine
Drug page: Shingrix
Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
Also known as: Herpes Zoster recombinant subunit vaccine, Shingrix
Adjusted Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies at 1 Month Post-second Dose of HZ/su Vaccination
Anti-gE antibodies were measured with enzyme linked immunosorbent assay (ELISA) and the results were expressed as GMC, in milli international units per milliliter (mIU/mL).
Time frame: At 1 month post-second dose of HZ/su vaccination (Day 91)
Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
Time frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
Time frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
Percentage of Participants With Seropositivity at Pre-vaccination and 1 Month Post-second Dose of HZ/su Vaccination
Seropositivity was defined as the percentage of participants whose antibody concentration was greater than or equal to the assay cut-off value (97 mIU/mL).
Time frame: Pre-vaccination (Day 1) and 1 month post-second dose of HZ/su vaccination (Day 91)
GMC of Anti-glycoprotein Antibodies at Pre-vaccination and 1 Month Post-second Dose of HZ/su Vaccination
Anti-gE antibodies were measured with ELISA and the results were expressed as GMC.
Time frame: Pre-vaccination (Day 1) and 1 month post-second dose of HZ/su vaccination (Day 91)
Mean Geometric Increase (MGI) of Anti-glycoprotein Antibodies at Pre-vaccination and 1 Month Post-second Dose of HZ/su Vaccination
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Anti-gE antibodies were measured with ELISA.
Time frame: At 1 month post-second dose of HZ/su vaccination (Day 91) compared to Pre-vaccination (Day 1)
Vaccine Response Rate (VRR) at 1 Month Post-second Dose of HZ/su Vaccination
The VRR was defined as the percentage of participants who had at least: a 4-fold increase post-vaccination anti-gE antibody concentration as compared to (over) the pre-vaccination anti-gE antibody concentration (for participants who were seropositive at pre-vaccination); or, a 4-fold increase post-vaccination anti-gE antibody concentration as compared to (over) the anti-gE antibody cut-off value for seropositivity (97 mIU/mL) (for participants who were seronegative at pre-vaccination).
Time frame: At 1 month post-second dose of HZ/su vaccination (Day 91)
GMT of RSV-A Neutralizing Titers (ED60) at Pre-vaccination and 1 Month After the RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
Time frame: At pre-vaccination (Day 1) and Day 31 for Co-administration Group and at pre-vaccination (Day 1) and Day 61 for Control Group
MGI of Respiratory Syncytial Virus-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Control Group)
GMT of RSV-B Neutralizing Titers (ED60) at Pre-vaccination and 1 Month After the RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
Time frame: At pre-vaccination (Day 1) and Day 31 for Co-administration Group and at pre-vaccination (Day 1) and Day 61 for Control Group
MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Control Group)
Percentage of Participants With Solicited Administration Site Adverse Events (AEs) After Each Vaccine Dose Administration
The solicited administration site events after vaccination included pain, erythema/redness, and swelling.
Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Days 1 and 61 for Co-Administration Group and at Days 1, 31 and 61 for Control group)
Percentage of Participants With Solicited Systemic AEs After Each Vaccine Dose Administration
The solicited systemic events after vaccination included arthralgia, fatigue, fever (pyrexia), headache, myalgia, shivering/chills, and gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain).
Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Days 1 and 61 for Co-Administration Group and at Days 1, 31 and 61 for Control group)
Percentage of Participants With Unsolicited Adverse Events
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs must had been communicated by participant/participant's caregiver(s) who had signed the informed consent. Unsolicited AEs included both serious and non-serious AEs.
Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after vaccine administration
Percentage of Participants With Serious Adverse Events (SAEs)
An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.
Time frame: From first dose of study vaccine administration (Day 1) up to 6 months after last dose of study vaccine administration, approximately 241 days
Percentage of Participants With Potential Immune-mediated Diseases (pIMDs)
The pIMD was a subset of adverse events of special interest that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From first dose of study vaccine administration (Day 1) up to 6 months after last dose of study vaccine administration, approximately 241 days
This study was conducted in adult participants aged 50 years and older, in 20 study sites.
| Milestone | Co-administration Group | Control Group |
|---|---|---|
| Started | 265 | 265 |
| Completed | 256 | 255 |
| Not completed | 9 | 10 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Protocol-specified withdrawal criterion met | 0 | 1 |
| Withdrew: Other | 1 | 1 |
Anti-gE antibodies were measured with enzyme linked immunosorbent assay (ELISA) and the results were expressed as GMC, in milli international units per milliliter (mIU/mL).
| mIU/mL | Co-administration Group | Control Group |
|---|---|---|
| Adjusted Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies at 1 Month Post-second Dose of HZ/su Vaccination | 49326.9 (44948.5 to 54131.7) | 61192.7 (55306.4 to 67705.5) |
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination | 8426.8 (7504.2 to 9462.7) | 9628.7 (8532.7 to 10865.4) |
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination | 10354.2 (9288.4 to 11542.3) | 10143.4 (9057.5 to 11359.4) |
Seropositivity was defined as the percentage of participants whose antibody concentration was greater than or equal to the assay cut-off value (97 mIU/mL).
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Pre-vaccination (Day 1) | 98.5 (96.1 to 99.6) | 97.3 (94.6 to 98.9) |
| 1 month post-second dose of HZ/su vaccination (Day 91) | 100.0 (98.2 to 100.0) | 100.0 (97.9 to 100.0) |
Anti-gE antibodies were measured with ELISA and the results were expressed as GMC.
| mIU/mL | Co-administration Group | Control Group |
|---|---|---|
| Pre-vaccination (Day 1) | 1739.4 (1503.4 to 2012.5) | 1492.2 (1278.5 to 1741.5) |
| 1 month post-second dose of HZ/su vaccination (Day 91) | 50235.2 (46013.4 to 54844.4) | 61204.7 (54959.6 to 68159.4) |
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Anti-gE antibodies were measured with ELISA.
| Ratio | Co-administration Group | Control Group |
|---|---|---|
| Mean Geometric Increase (MGI) of Anti-glycoprotein Antibodies at Pre-vaccination and 1 Month Post-second Dose of HZ/su Vaccination | 28.24 (23.66 to 33.71) | 43.24 (34.97 to 53.47) |
The VRR was defined as the percentage of participants who had at least: a 4-fold increase post-vaccination anti-gE antibody concentration as compared to (over) the pre-vaccination anti-gE antibody concentration (for participants who were seropositive at pre-vaccination); or, a 4-fold increase post-vaccination anti-gE antibody concentration as compared to (over) the anti-gE antibody cut-off value for seropositivity (97 mIU/mL) (for participants who were seronegative at pre-vaccination).
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Vaccine Response Rate (VRR) at 1 Month Post-second Dose of HZ/su Vaccination | 92.9 (88.4 to 96.1) | 96.5 (92.5 to 98.7) |
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Pre-vaccination (Day 1) | 1005.4 (909.1 to 1111.9) | 961.2 (860.8 to 1073.4) |
| Day 31 | 8553.3 (7568.7 to 9666.1) | — |
| Day 61 | — | 9689.4 (8561.7 to 10965.7) |
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
| Ratio | Co-administration Group | Control Group |
|---|---|---|
| MGI of Respiratory Syncytial Virus-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination | 8.55 (7.44 to 9.82) | 9.91 (8.55 to 11.49) |
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. The ED60 was defined as the dose that produced an effect in 60% of the population.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Pre-vaccination (Day 1) | 1148.8 (1042.2 to 1266.3) | 1167.9 (1033.5 to 1319.8) |
| Day 31 | 10521.3 (9411.3 to 11762.2) | — |
| Day 61 | — | 10352.2 (9122.8 to 11747.3) |
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
| Ratio | Co-administration Group | Control Group |
|---|---|---|
| MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination | 9.01 (7.93 to 10.24) | 8.69 (7.50 to 10.07) |
The solicited administration site events after vaccination included pain, erythema/redness, and swelling.
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Pain at injection site, HZ/su dose 1, given at Day 1 | 67.6 (61.4 to 73.3) | 59.8 (53.4 to 65.9) |
| Pain at injection site, RSV dose, given at Day 1 | 63.1 (56.8 to 69.1) | — |
| Pain at injection site, RSV dose, given at Day 31 | — | 49.6 (43.0 to 56.1) |
| Pain at injection site, HZ/su dose 2, given at Day 61 | 57.3 (50.6 to 63.9) | 63.4 (56.9 to 69.6) |
| Erythema at injection site, HZ/su dose 1, given at Day 1 | 14.6 (10.5 to 19.6) | 13.1 (9.2 to 18.0) |
| Erythema at injection site, RSV dose, given at Day 1 | 7.9 (4.9 to 12.0) | — |
| Erythema at injection site, RSV dose, given at Day 31 | — | 7.6 (4.6 to 11.8) |
| Erythema at injection site, HZ/su dose 2, given at Day 61 | 16.0 (11.5 to 21.5) | 11.9 (8.1 to 16.8) |
| Swelling at injection site, HZ/su dose 1, given at Day 1 | 8.7 (5.5 to 12.9) | 8.8 (5.6 to 13.0) |
| Swelling at injection site, RSV dose, given at Day 1 | 6.0 (3.4 to 9.6) | — |
| Swelling at injection site, RSV dose, given at Day 31 | — | 5.5 (3.0 to 9.2) |
| Swelling at injection site, HZ/su dose 2, given at Day 61 | 8.9 (5.5 to 13.4) | 8.5 (5.3 to 12.8) |
The solicited systemic events after vaccination included arthralgia, fatigue, fever (pyrexia), headache, myalgia, shivering/chills, and gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain).
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Fever, Dosing at Day 1 | 8.9 (5.7 to 13.1) | 6.2 (3.6 to 9.8) |
| Fever, Dosing at Day 31 | — | 3.3 (1.4 to 6.3) |
| Fever, Dosing at Day 61 | 3.0 (1.2 to 6.2) | 7.4 (4.4 to 11.5) |
| Headache, Dosing at Day 1 | 37.2 (31.3 to 43.4) | 30.0 (24.5 to 36.0) |
| Headache, Dosing at Day 31 | — | 22.9 (17.8 to 28.6) |
| Headache, Dosing at Day 61 | 30.9 (25.0 to 37.3) | 33.3 (27.4 to 39.6) |
| Fatigue, Dosing at Day 1 | 48.8 (42.6 to 55.1) | 36.2 (30.3 to 42.3) |
| Fatigue, Dosing at Day 31 | — | 31.8 (26.1 to 38.1) |
| Fatigue, Dosing at Day 61 | 39.6 (33.2 to 46.2) | 46.5 (40.1 to 53.0) |
| Myalgia, Dosing at Day 1 | 51.9 (45.7 to 58.2) | 40.4 (34.4 to 46.6) |
| Myalgia, Dosing at Day 31 | — | 26.9 (21.5 to 33.0) |
| Myalgia, Dosing at Day 61 | 37.0 (30.7 to 43.5) | 41.6 (35.3 to 48.0) |
| Arthralgia, Dosing at Day 1 | 24.0 (18.9 to 29.7) | 16.2 (11.9 to 21.2) |
| Arthralgia, Dosing at Day 31 | — | 12.7 (8.8 to 17.5) |
| Arthralgia, Dosing at Day 61 | 20.9 (15.8 to 26.7) | 21.0 (16.0 to 26.7) |
| Chills, Dosing at Day 1 | 22.9 (17.9 to 28.5) | 12.7 (8.9 to 17.4) |
| Chills, Dosing at Day 31 | — | 13.1 (9.1 to 17.9) |
| Chills, Dosing at Day 61 | 23.0 (17.8 to 29.0) | 25.9 (20.5 to 31.9) |
| Gastrointestinal Symptoms, Dosing at Day 1 | 15.9 (11.7 to 20.9) | 15.0 (10.9 to 19.9) |
| Gastrointestinal Symptoms, Dosing at Day 31 | — | 11.4 (7.7 to 16.1) |
| Gastrointestinal Symptoms, Dosing at Day 61 | 9.1 (5.7 to 13.6) | 12.3 (8.5 to 17.2) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs must had been communicated by participant/participant's caregiver(s) who had signed the informed consent. Unsolicited AEs included both serious and non-serious AEs.
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Percentage of Participants With Unsolicited Adverse Events | 23.4 (18.4 to 29.0) | 30.2 (24.7 to 36.1) |
An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 4.9 (2.6 to 8.2) | 2.3 (0.8 to 4.9) |
The pIMD was a subset of adverse events of special interest that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Percentage of participants | Co-administration Group | Control Group |
|---|---|---|
| Percentage of Participants With Potential Immune-mediated Diseases (pIMDs) | 0.4 (0.0 to 2.1) | 0.8 (0.1 to 2.7) |
Collected over Solicited AEs were collected up to Day 7 post each vaccination. Unsolicited AEs were collected up to Day 30 post each vaccination. SAEs and pIMDs were collected throughout the study period from Day 1 up to 6 months post last vaccination (approximately up to 241 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-administration Group | 0/265 (0%) | 13/265 (4.9%) | 240/265 (90.6%) |
| Control Group | 0/265 (0%) | 6/265 (2.3%) | 235/265 (88.7%) |
| Event | Co-administration Group | Control Group |
|---|---|---|
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/265 | 0/265 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/265 | 0/265 |
| AnaemiaBlood and lymphatic system disorders | 0/265 | 1/265 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/265 | 1/265 |
| Myocardial infarctionCardiac disorders | 1/265 | 0/265 |
| Atrial fibrillationCardiac disorders | 1/265 | 0/265 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/265 | 1/265 |
| AppendicitisInfections and infestations | 0/265 | 1/265 |
| Pneumonia influenzalInfections and infestations | 1/265 | 0/265 |
| CystitisInfections and infestations | 1/265 | 0/265 |
| Event | Co-administration Group | Control Group |
|---|---|---|
| Injection site painGeneral disorders | 204/265 | 197/265 |
| FatigueGeneral disorders | 149/265 | 156/265 |
| MyalgiaMusculoskeletal and connective tissue disorders | 153/265 | 155/265 |
| HeadacheNervous system disorders | 119/265 | 138/265 |
| ChillsGeneral disorders | 85/265 | 90/265 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 86/265 | 78/265 |
| Injection site erythemaGeneral disorders | 59/265 | 57/265 |
| DiarrhoeaGastrointestinal disorders | 30/265 | 43/265 |
| Injection site swellingGeneral disorders | 38/265 | 40/265 |
| PyrexiaGeneral disorders | 29/265 | 40/265 |
Exposed set included all participants in the enrolled set who received at least 1 study intervention.
| Age, Continuous(years) | Co-administration Group | Control Group | Total |
|---|---|---|---|
| Mean | 63.9 ± 8.56 | 63.9 ± 8.73 | 63.9 ± 8.64 |
| Sex: Female, Male(Participants) | Co-administration Group | Control Group | Total |
|---|---|---|---|
| Female | 146 | 146 | 292 |
| Male | 119 | 119 | 238 |
| Ethnicity (NIH/OMB)(Participants) | Co-administration Group | Control Group | Total |
|---|---|---|---|
| Hispanic or Latino | 28 | 30 | 58 |
| Not Hispanic or Latino | 237 | 235 | 472 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Jul 2023 to primary completion in Feb 2024, 6 months.
Results were first posted in Apr 2025, 1 year 1 month after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 6 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arexvy · Shingrix
Respiratory Syncytial Virus Infections →